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Objective: To determine the degree to which swallowing valproate (VP) tablets is an issue, 
the proportion of patients who would prefer an alternative formulation, and the predictors of 
preference.
Methods: A quantitative telephone survey of eligible adults (n = 400, 18 years old) who 
currently take (n = 236) or previously took (n = 164) VP tablets within the past 6 months was 
conducted.
Results: More than half of the patients indicated that VP tablets were ‘uncomfortable to 
swallow’ (68.5%, n = 274) and were ‘very interested’ (65.8%, n = 263) in medications that 
were easier to swallow. When choosing conceptually between taking VP tablet once/day or an 
equally safe and effective but significantly smaller soft gel capsule twice per day, the 82.8%, 
(n = 331) preferred the soft gel capsule. In the multivariate regression analysis, perceiving soft 
gel capsules to be easier to swallow (OR = 73.54; 95% CI = 15.01 to 360.40) and taking VP 
more frequently (OR = 2.02; 95% CI = 1.13 to 3.61) were significant predictors of soft gel 
capsule treatment preference.
Conclusion: VP users would prefer a formulation that is easier to swallow, even if it is needed 
to be taken twice per day. When choosing between medications with similar efficacy and safety, 
physicians can consider patient preferences to optimize conditions for medication adherence.
Keywords: patient preference, valproate formulations, tablet characteristics
Introduction
Bipolar disorder, epilepsy, and migraine headache are prevalent and costly conditions 
for which valproate (VP) is often prescribed. Studies of US adults estimate bipolar 
prevalence at 3.7% to 5% with annual total cost estimates ranging from US$10 billion 
to US$45 billion.1–6 Epilepsy affects about 2.6 million Americans or just less than 1% 
of the general population, producing an estimated US$1.8 billion in direct medical 
costs and US$9.3 billion in indirect costs annually (1995 US$).7–9 Migraine headache 
is, by far, the most prevalent of these three disorders, affecting an estimated 17.2% 
of women and 6.0% of men in the US with the indirect costs to American employers 
estimated at approximately US$13 billion annually.10–13
Adherence with prescribed treatment is challenging for patients with these chronic 
mental and neurological disorders, which all require long-term medication adher-
ence to optimize outcomes and reduce costs.14–20 Studies find that approximately 
half of patients diagnosed with bipolar disorder are either partially adherent or 
nonadherent to pharmacological therapy.21–23 Furthermore, 30% to 40% of bipolar 
patients who actively attempt to adhere to treatment are only partially successful.17 Patient Preference and Adherence 2009:3 162
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Estimates of treatment adherence among patients diagnosed 
with epilepsy were examined in observational studies 
finding medication noncompliance rates ranging from 
59% to 71%.24,25 Adherence rates to pharmacologic pro-
phylactic treatment for migraine headache was found 
to range from 35% to 64% in cohorts of adult Swedish 
migraineurs.26,27 Treatment nonadherence among patients 
with these conditions is likely to be a substantial contribu-
tor to unfavorable outcomes such as increased frequency 
of seizures24,25 and may consequently result in high direct 
and indirect health-related costs.28
Given the significant impact of therapeutic adherence on 
outcomes and costs, health care providers must recognize that 
the patient is the end user and ultimate decision maker when 
it comes to taking medications and that patient satisfaction 
with a medication strongly affects that decision.29,30 While 
medication efficacy and safety are of utmost importance, 
characteristics such as tablet size, shape and ease-of-
swallowing can affect patients’ treatment preference and 
adherence.31,32 A study of patients with anxiety disorder 
found that significantly more patients preferred the capsule 
form of chlordiazepoxide as compared to the tablet form.31 
A 2003 representative survey of US adults (N = 679) regard-
ing difficulty swallowing pill-form medications found 
that approximately 40% of respondents had experienced 
difficulty swallowing pills.33 Among those having difficulty 
swallowing pills, the majority described feeling that it was 
‘stuck in the throat’ (80%), having a ‘bad aftertaste in the 
mouth’ (48%), or ‘gagging’ (32%).33 This study supports the 
assertion that difficulty swallowing pills negatively impacts 
medication adherence, as it found that those reporting this 
problem also reported delaying doses (14%), skipping doses 
(8%), and discontinuing medication (4%) due to difficulty 
swallowing it.33 One in five adults surveyed reported they 
had hesitated to take a pill because they thought they may 
have trouble swallowing it, with the majority attributing 
this perception to pill size (84%) and/or pill shape (29%).33 
One in 10 respondents reported choosing pills based on how 
difficult they might be to swallow, with women (14%) being 
substantially more likely to use this criterion than men (4%).33 
Thus, patient acceptance of tablets and their adherence could 
be affected by size and shape of the tablet.
Valproate (VP) is commonly used to control bipolar 
disorder, epilepsy, and migraine prophylaxis and is most 
often prescribed in tablet form. The objective of the 
current research was to assess whether a VP formulation 
(‘Product X’) with alternative soft gel characteristics such 
as smaller size, different composition, and different shape 
impact patient perceptions about ease of swallowing and 
treatment preference.
Methods
We conducted a quantitative telephone survey of adults 
(N = 400, 18 years old) who currently (n = 236) or 
previously (n = 164) took VP tablets (125 mg, 250 mg, or 
500 mg) in the past 6 months. Participants were recruited 
using two different sources, a national on-line consumer 
survey panel and referrals from the National Association 
of the Mentally Ill. After the participant completed a short 
on-line survey to determine eligibility, qualified participants 
were invited to complete a structured interview about 
medication use, perceived pill characteristics, and medica-
tion preferences. A group of 14 telephone interviewers were 
rigorously trained to complete the survey according to 
nationally recognized marketing research standards. Prior 
to beginning the telephone interview, all participants were 
re-screened to ensure that they met the following eligibility 
criteria: 18 years old; took or have taken VP in the past 
6 months; currently take or have taken VP for at least 
2 months; took or have taken 500 mg VP tablet; have no 
member of the immediate household employed by or under 
contract for any pharmaceutical manufacturer (Figure 1). 
Informed consent was obtained through an online form. 
Respondents received an honorarium of US$35 to US$75 as 
a participation incentive (to enhance recruiting, the offered 
honorarium increased over time).
The survey contained 36 questions and took an 
average of 15 minutes to complete. The questionnaire 
was comprised of demographic questions, questions about 
perceived medication characteristics, medication use 
patterns, and preferences for medication characteristics 
(size, shape, and perceived ease of swallowing). In the 
univariate analyses of variance, chi-square and t-tests were 
used for categorical and continuous variables respectively. 
Multivariate logistic regression analyses were conducted 
to determine significant predictors of treatment preference. 
Variables that were statistically significant in the univariate 
analyses were included in the multivariate model. The 
dependent variable in multivariate analyses was ‘Prefer 
Product X’ (‘yes’ or ‘no’).
Results
Of 579 persons who initially responded, 400 were eligible 
to complete the telephone survey (Figure 1). More than half 
(56%) of survey respondents were between 35 and 54 years 
old with only 6% being younger than 24 years old and Patient Preference and Adherence 2009:3 163
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only 1.2% being older than 65 years. Nearly two-thirds 
of respondents reported having US$50,000 in annual 
household income. Of the respondents, 42% were married, 
32% had never been married, and 22% were divorced. 
Overall, respondents were well-educated, with 67% reporting 
they had attended some college or had either a 2-year or 
4-year college degree. Most respondents also had health 
insurance benefits, with over 75% reporting that all or most 
of their treatment costs were paid for by private insurance, 
Medicare, or Medicaid (Table 1).
The majority of respondents were prescribed VP to control 
bipolar disorder (n = 260, 65.0%). The remaining participants 
took VP primarily to prevent migraine headache (12.5%, 
n = 50), control epilepsy (11.8%, n = 47), or ‘other conditions’ 
(10.8%, n = 43). Respondents reported taking more than one 
VP tablet daily [mean (SD) = 2.5 (1.2) and 88.0% reported 
taking multiple other prescription medications daily [mean 
(SD) = 5.2 (3.6)] (Table 2).
Nearly half of the respondents discontinued taking VP as 
a result of the side effects they experienced (48.5%, n = 80), 
primarily weight gain (24.8%). In addition, slightly more 
than a third said that they stopped because it did not reduce 
their symptoms (35.2%, n = 58) (Figure 2). The majority of 
respondents reported their VP tablet was ‘uncomfortable to 
swallow’ (68.5%, n = 274) and were ‘very interested’ (65.8%, 
n = 263) or ‘somewhat interested’ (18.0%, n = 72) in taking 
a soft gel medication that appeared to be easier to swallow. 
When presented conceptually with a choice between taking 
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Figure 1 Participant screening process (initial sample size = 579).
Note: From the initial pool of 579 patients, 20 patients entered the survey but did not answer any questions, hence were excluded from the study.Patient Preference and Adherence 2009:3 164
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Table 1 Respondent characteristics (n = 400)
Characteristics Overall 
(N = 400)
Current VP users 
(N = 236)
Previous VP 
users (N = 164)
Age group
  18–24 years 24 (6.0%) 14 (5.9%) 10 (6.1%)
  25–34 years 84 (21.0%) 53 (22.5%) 31 (18.9%)
  35–44 years 113 (28.3%) 64 (27.1%) 49 (29.9%)
  45–54 years 111 (27.7%) 61 (25.8%) 50 (30.5%)
  55–64 years 63 (15.7%) 39 (16.6%) 24 (14.6%)
  65 and Above 5 (1.3%) 5 (2.1%) –
Sex
  Male 118 (29.5%) 92 (38.9%) 26 (15.8%)
  Female 282 (70.5%) 144 (61.1%) 138 (84.2%)
Marital status
  never married 121 (30.2%) 74 (31.4%) 47 (28.6%)
  Married 174 (43.5%) 104 (44.1%) 70 (42.7%)
  Divorced 95 (23.8%) 49 (20.7%) 46 (28.1%)
  Widowed 9 (2.2%) 8 (3.4%) 1 (0.6%)
  Prefer not to answer 1 (0.3%) 1 (0.4%) –
Annual household incomea
  Less than $15,000 78 (19.5%) 45 (19.1%) 33 (20.1%)
  $15,000–$29,999 93 (23.2%) 44 (18.6%) 49 (30.0%)
  $30,000–$49,999 77 (19.2%) 49 (20.8%) 28 (17.1%)
  $50,000–$69,999 59 (14.8%) 34 (14.4%) 25 (15.2%)
  $70,000–$99,999 46 (11.5%) 34 (14.4%) 12 (7.3%)
  $100,000 or more 36 (9.0%) 23 (9.8%) 13 (7.9%)
  Don’t know/Prefer not to answer 11 (2.8%) 7 (2.9%) 4 (2.4%)
Education
  some high school 10 (2.5%) 6 (2.5%) 4 (2.4%)
  high school degree or geD 62 (15.5%) 39 (16.6%) 23 (14.0%)
  some college 148 (37.0%) 78 (33.1%) 70 (42.7%)
  2- or 4-year college degree 121 (30.3%) 69 (29.2%) 52 (31.7%)
  Postgraduate work 58 (14.4%) 43 (18.2%) 15 (9.2%)
  Prefer not to answer 1 (0.3%) 1 (0.4%) –
Prescription insurance coverage
  Pay 100% out of pocket 28 (7.0%) 9 (3.8%) 19 (11.6%)
    Have insurance but pay significant costs 51 (12.7%) 32 (13. 6%) 19 (11.6%)
  out of pocket
    have insurance that pays all/most of costs 178 (44.5%) 113 (47.9%) 65 (39.6%)
  have Medicare/Medicaid 142 (35.5%) 81 (34.3%) 61 (37.2%)
  Other/don’t know 1 (0.3%) 1 (0.4%) –
aUs$.
Abbreviation: geD, general educational Development.
their current VP tablet once daily and taking a smaller, soft 
gel capsule (‘Product X’) with equivalent safety and effec-
tiveness twice daily, the majority (82.8%, n = 331) preferred 
the soft gel capsule medication. An even larger majority 
of respondents (85.3%, n = 341) indicated preferring the 
soft gel medication when asked, ‘If both medications were 
available when you first began taking VP, which would you 
have preferred?’ (Table 3)
Univariate analysis of variance revealed that respondents 
preferring the soft gel capsule took VP tablets more times per 
day (P = 0.05) and were significantly more likely to: perceive 
that soft gel capsules were easier to swallow (P  0.001); Patient Preference and Adherence 2009:3 165
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Table 2 Valproate (VP) utilization patterns
Utilization Overall (n = 400) Current   VP 
users (n = 236)
Previous   VP 
users (n = 164)
Primary reasons for taking VP
  epilepsy 
  Bipolar disorder 
  Migraines 
  Other
47 (11.7%) 
260 (65.0%) 
50 (12.5%) 
43 (10.8%)
29 (12.3%)  
151 (63.9%)  
32 (13.6%)  
24 (10.2%)
18 (10.9%) 
109 (66.5%) 
18 (11.0%)  
19 (11.6%)
Type of VP (currently using  
or ever used)
  Tablet form, several times per day  
  Tablet form, once daily
243 (60.8%) 
266 (66.6%)
133 (56.4%) 
178 (75.4%)
110 (67.1%) 
88 (53.7%)
Total milligrams of   VP per day
  Mean (sD) 
  [Median]
1176.38 (594.59) 
[1000.00]
1201.06 (574.36) 
[1000.00]
1140.85 (622.61) 
[1000.00]
Number of   VP tablets per day
  Mean (sD) 
  [Median]
2.46 (1.23) 
[2.00]
2.53 (1.19) 
[2.00]
2.37 (1.27) 
[2.00]
Times per day taking VP
  Mean (sD) 
  [Median]
1.60 (0.70) 
[1.00]
1.50 (0.67) 
[1.00]
1.73 (0.73) 
[2.00]
Concurrent use of other  
prescription medications
  Yes 352 (88.0%) 215 (91.1%) 137 (83.5%)
  no 48 (12.0%) 21 (8.9%) 27 (16.5%)
Total number of medications  
(including VP) daily
  Mean (sD) 
  [Median]
5.24 (3.63) 
[4.00]
5.58 (3.68) 
[4.00]
4.71 (3.51) 
[4.00]
Use of another medication  
for condition prior to VP
  Yes 266 (66.5%) 153 (64.8%) 113 (68.9%)
  no 134 (33.5%) 83 (35.2%) 51 (31.1%)
be female (P = 0.02); be married (P = 0.0001); and have a 
college degree (P = 0.006) than those preferring VP tablets. 
(Table 4) In the multivariate regression analysis, perceiving 
soft gel capsules as being easier to swallow (P  0.001), 
taking VP more times per day (P = 0.02), and being currently 
married (P = 0.02) were significant predictors of soft gel 
capsule treatment preference (Table 5).
Respondents preferring the soft gel capsule to the tab-
let formulation did not differ by age, annual household 
income, or prescription insurance coverage (Table 4). Those 
preferring soft gel capsules to tablets also did not differ by 
primary reason for taking VP, total mgs of VP taken per day, 
number of VP tablets taken per day, concurrent use of other 
prescription medications, or whether they had treated the 
primary condition with another medication prior to taking 
VP (Table 4).
The respondents (n = 59) who preferred the VP tablet 
even if both medications had been available when they 
were initially prescribed VP, were asked to give specific 
reasons for this preference. The most common reason given 
was preference for a once daily dose (34.5%), followed by 
feeling that it ‘works well’ (27.6%), preferring a ‘name 
brand’ (8.6%), ‘don’t care’ (6.9%), ‘physician’s choice’ 
(6.9%), ‘don’t like gelcaps’ (6.9%), and ‘side effects’ (5.2%) 
(Figure 3).
The respondents (n = 341) who indicated preferring the 
soft gel capsule (had it been available when they were initially 
prescribed VP) were also asked to give specific reasons for 
this preference. The most common reason given was pref-
erence for a ‘smaller pill’ (61.2%), preferring an oral form 
that was ‘easier to swallow’ (55.1%), preferring a ‘soft gel’ 
(28.9%), feeling that it was ‘faster acting’ (8.8%), feeling Patient Preference and Adherence 2009:3 166
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3.6%
4.8%
8.5%
12.7%
35.2%
48.5%
0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0%
Physician Decision
Cost/Insurance Coverage
Voluntary Reasons
Switched Medication
Did Not Reduce Symptoms
Side Effects
Percent of respondents
Figure 2 Reasons for discontinuing valproate (VP) (n = 164, multiple responses were accepted; only top responses are shown).
Table 3 Respondent perceptions and treatment preference
Overall (n = 400) Current   VP 
users (n = 236)
Previous   VP 
users (n = 164)
Uncomfortable to swallow VP    
  Yes 274 (68.5%) 162 (69.6%) 112 (68.3%)
  no 126 (31.5%) 74 (31.4%) 52 (31.7%)
Interest in taking a tablet that is  
easier to swallow
  Very interested 263 (65.8%) 164 (69.5%) 99 (60.4%)
  somewhat interested  72 (18.0%) 41 (17.4%) 31 (18.9%)
  neither interested nor uninterested  45 (11.2%) 22 (9.3%) 23 (14.0%)
  somewhat uninterested 6 (1.5%) 2 (0.9%) 4 (2.4%)
  Very uninterested 14 (3.5%) 7 (2.9%) 7 (4.3%)
Appears to be easier to swallow
  VP 18 (4.5%) 11 (4.7%) 7 (4.3%)
  Product X 382 (95.5%) 225 (95.3%) 157 (95.7%)
Want to be made aware of  
Product X soft gel capsule
  Yes 312 (78.0%) 180 (76.3%) 132 (80.5%)
  no 88 (22.0%) 56 (23.7%) 32 (19.5%)
Prefer if these medications were  
equal in effectiveness and side effects
  VP 69 (17.2%) 40 (16.9%) 29 (17.7%)
  Product X 331 (82.8%) 196 (83.1%) 135 (82.3%)
Prefer if these medication were  
equal in effectiveness and side  
effects, and comparable in costs
  VP 63 (15.87%) 38 (16.1%) 25 (15.2%)
  Product X 337 (84.3%) 198 (83.9%) 139 (84.8%)
Treatment preferencea
  VP 59 (14.7%) 36 (15.2%) 23 (14.0%)
  Product X 341 (85.3%) 200 (84.8%) 141 (86.0%)
aTreatment preference was assessed using the following question: ‘If both these medications were available when you first started taking VP, which would you have preferred 
your doctor to prescribe?’Patient Preference and Adherence 2009:3 167
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Table 4 Treatment preference (univariate analyses)
Variables Treatment preference [N (%)] P-value
VP (N = 59) Product X (N = 341)
VP Users
  current 36 (61.1%) 200 (58.6%) 0.73
  Previous 23 (38.9%) 141(41.4%)
Primary reasons for taking VP
  epilepsy 7 (11.9%) 40 (11.7%) 0.99
  Bipolar disorder 39 (66.1%) 221 (64.8%)
  Migraines 7 (11.9%) 43 (12.6%)
  Other 6 (10.1%) 37 (10.9%)
Type of VP used      
  VP immediate release 16 (27.1%) 118 (34.6%) 0.14
  VP extended release 30 (50.9%) 127 (37.2%)
  Both 13 (22.0%) 96 (28.2%)
Total milligrams of VP per day
  Mean (sD) 1222.46 (681.92) 1168.40 (578.90) 0.52
  [Median] [1000.00] [1000.00]
Number of VP tablets per day
  Mean (sD) 2.53 (1.35) 2.45 (1.21) 0.66
  [Median] [2.00] [2.00]
Times per day taking VP
  Mean (sD) 1.44 (0.68) 1.62 (0.70) 0.05
  [Median] [1.00] [1.00]
Concurrent use of other 
prescription medications
  Yes 54 (91.5%) 298 (87.4%) 0.37
  no 5 (8.5%) 43 (12.6%)
Used another medication for 
condition prior to VP
  Yes 39 (66.1%) 227 (66.6%) 0.94
  no 20 (33.9%) 114 (33.4%)
Appears to be easier to swallow    
  VP 16 (27.1%) 2 (0.6%) 0.001
  Product X 43 (72.9%) 339 (99.4%)
Age group            
  18–24 years 3 (5.1%) 21 (6.2%) 0.92
  25–34 years 12 (20.3%) 72 (21.1%)
  35–44 years 18 (30.5%) 95 (27.9%)
  45–54 years 18 (30.5%) 93 (27.3%)
  55–64 years 6 (10.2%) 57 (16.6%)
  65 years 2 (3.4%) 3 (0.9%)
Sex    
  Male 25 (42.4%) 93 (27.3%) 0.02
  Female 34 (57.6%) 248 (72.7%)
Marital status
  Married 18 (30.5%) 156 (45.8%) 0.0001
  not married 30 (50.9%) 91 (26.7%)
  Divorced/Widowed 10 (16.9%) 94 (27.5%)
  Prefer not to answer 1 (1.7%) 0 (0.0%)
(Continued)Patient Preference and Adherence 2009:3 168
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that it would be ‘easier to digest’ (7.1%), and feeling that it 
would be ‘easier to store’ (5.3%) (Figure 4).
Discussion
Despite the fact that tablet-related characteristics, such as 
difficulties in swallowing tablets due to size and shape, seem 
to be a well-known problem among patients (negatively 
affecting their treatment acceptance and preference), few 
studies have addressed this issue. The finding from this 
survey-based study indicated that the majority of patients 
currently or previously treated with VP tablets reported 
difficulty swallowing them, is of interest due to its potential 
usefulness in improving clinical practice and patient 
outcomes. Results indicate that these patients are interested 
in knowing about medication with similar safety and efficacy 
that is formulated as a smaller, soft gel capsule. Given a 
choice between treatment with VP tablets or smaller, soft 
gel capsules with similar efficacy and safety, those who 
perceived the soft gel capsules to be easier to swallow would 
prefer treatment with that medication despite having to take 
it twice daily.
Many patients fail to voluntarily express important 
treatment preferences or barriers to adherence, such as 
difficulty swallowing medication during the clinical 
encounter. Data indicate that less than a quarter of people 
who have difficulty swallowing their pills discuss the 
problem with a health professional.33 The first nationally 
representative survey of pill-swallowing difficulty finds 
that only 14% of people who have difficulty taking oral 
medications indicate that their health provider has brought 
up the topic, and only 10% report initiating conversation 
about this difficulty themselves.33 While there are likely to 
be many contributing factors to this reluctance, it has been 
attributed to patients’ perceptions that physicians are focused 
on ‘treating numbers’ – a result of the increased emphasis 
on guideline-driven prescribing practices.34,35
It is well documented that patient non-adherence to 
medication is a substantial barrier to the effective treatment 
of bipolar disorder, epilepsy, and migraine prophylaxis. 
However, data indicate that prescribing clinicians underes-
timate the extent of this problem.22 One study of medication 
adherence in bipolar patients (N = 429) found that although 
57% reported missing all or some medication doses in the 
past 10 days, prescribing psychiatrists considered only 6% 
of these patients to be ‘treatment non-adherent’.22, There 
is a similar tendency to overestimate patient adherence 
with therapy among physicians prescribing for epilepsy 
treatment36 and migraine prophylaxis. Thus, for these 
Table 4 (Continued)
Variables Treatment preference [N (%)] P-value
VP (N = 59) Product X (N = 341)
Annual household incomea
  $30,000 27 (45.8%) 144 (42.2%) 0.34
  $30,000–$49,999 14 (23.7%) 63 (18.5%)
  $50,000–$69,999 5 (8.5%) 54 (15.8%)
  $70,000 10 (16.9%) 72 (21.1%)
  Don’t know/Prefer not to answer 3 (5.1%) 8 (2.4%)
Education
  some high school 3 (5.1%) 7 (2.1%) 0.006
  high school degree or geD 8 (13. 6%) 54 (15.8%)
  2- or 4-year college degree 9 (15.2%) 112 (32.8%)
  Postgraduate work 13 (22.0%) 45 (13.2%)
  Don’t know/Prefer not to answer 1 (1.7%) 0 (0.0%)
Prescription insurance coverage          
  Pay 100% out of pocket 3 (5.1%) 25 (7.4%) 0.12
  Have insurance but pay significant costs out of pocket 5 (8.5%) 46 (13.5%)
  have insurance that pays all/most of costs 21 (35.6%) 157 (46.0%)
  have Medicare/Medicaid 30 (50.8%) 112 (32.8%)
  Other/Don’t know 0 (0.0%) 1 (0.3%)
Notes: P values in bold indicate significant at P  0.05.
aUs$.
Abbreviation: geD, general educational Development.Patient Preference and Adherence 2009:3 169
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Table 5 Predictors of treatment preference (multivariate analysis)
Variables β estimate Standard error P-value Odds ratio 95% CI
Lower CI Higher CI
Times per day taking VP 0.70 0.30 0.02 2.02 1.13 3.61
Appears to be easier to 
swallow
   
  Product X 4.29 0.81 0.001 73.54 15.01 360.40
  VP – – – 1.00 – –
Sex  
  Female 0.63 0.35 0.07 1.87 0.94 3.73
  Male – – – 1.00 – –
Marital status
  Married 0.94 0.39 0.02 2.56 1.19 5.47
  Divorced/Widowed 0.68 0.44 0.11 1.98 0.84 4.66
  never Married – – – 1.00 – –
Education    
  high school degree or geD   0.59 1.12 0.59 1.81 0.20 16.08
  some college –0.18 1.03 0.86 0.83 0.11 6.28
  2- or 4-year college degree   0.68 1.07 0.53 1.98 0.24 16.29
  Postgraduate work –0.33 1.06 0.76 0.72 0.09 5.76
  some high school – – – 1.00 – –
Abbreviations: CI, confidence interval; GED, General Educational Development.
disorders, medication non-adherence could be a larger 
problem, making it critical to recognize the problems 
faced by the patients while taking medications, barriers 
to treatment acceptance, and factors affecting patient 
preference.
A supportive therapeutic alliance between patients and 
clinicians is known to improve patient adherence with 
treatment in the psychiatric and neurological disorders 
addressed here.14,18,24–26,37–41 An important opportunity 
exists for physicians to build the therapeutic alliance and 
potentially improve treatment adherence by engaging the 
patient in shared decision making regarding prescription 
medications.23,25,41,42 Studies of other medications further 
support the link between medication characteristics 
and adherence, finding that changes in oral medication 
formulation affect patient adherence to prescribed 
therapy.32 By engaging the patient in prescribing decisions 
and discussing factors that may improve adherence, 
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Figure 4 Reasons for Product X (soft gel) preference (n = 341).
providers can optimize therapy to produce more effective 
management and greater improvements in the patient’s 
condition.29
The current study has several limitations. The US$35 
to US$75 participation incentive that respondents 
received may have had effects on the results, though since 
it was not a focus of the study, the reasons cannot be 
explained. Similarly, additional analysis of marriage status, 
a statistically significant predictor of treatment preference, 
was not within the scope of the study. Most importantly, 
respondent demographics are not representative, thus, the 
results can not be generalized to other populations. It is likely 
that reliance on the internet for initial patient recruitment 
accounts for the non-representative characteristics of our 
respondents including high proportions of young and 
middle-aged persons who were college educated and had 
health insurance coverage for prescription medications. 
Time since VP cessation was not evaluated. It is possible 
that participants who stopped taking VP 6 months ago may 
have answered questions differently had they been asked 
nearer to when they took it.
Conclusions
The goal of any treatment is to offer an approach which elimi-
nates or reduces the number and frequency of symptoms and 
produces the best possible quality-of-life while avoiding drug 
interactions and side effects. Given the significant impact of 
therapeutic adherence on clinical outcomes and health-related 
costs, providers must recognize the facts that patients make 
the ultimate treatment decision (that is to take medication 
as prescribed or not) and that patient satisfaction with a 
medication strongly affects that decision.29,30 In this study, 
users of VP indicated that they would prefer a formulation 
that is easier to swallow, even if it needed to be taken twice 
per day. This study provides preliminary data upon which 
further investigation should be based. Additional research 
is needed to clarify issues of patient medication preferences 
and to better quantify the impact of oral formulations that 
are easy to swallow and smaller in size on patient adherence 
with therapy.
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